FOXO TECHNOLOGIES Stock Price, News & Analysis

FOXO Technologies (OTC: FOXO) year-end review (Dec 15, 2025) highlights 2025 operational growth, acquisitions, and financial improvements. Key operating notes: Myrtle Recovery reached a 2025 average daily census of 28 (93% occupancy) with projected 550 admissions vs 195 in 2024 and served patients from 63 of 95 Tennessee counties. Scott County Community Hospital expects >7,000 ER visits, >3,500 outpatient visits and ~300 inpatient stays in 2025. Vector BioSource is expected to generate ~$1M net revenue in 2025. Financials: ~$12M net revenues for nine months ended Sept 30, 2025 and expected to exceed $15M for full year; equity rose from $5.3M (Dec 31, 2024) to $20.2M (Sept 30, 2025); debt reduced from $10.2M to $7.1M. Corporate actions included settling a $2.3M liability and converting ~$3.5M PIK notes to preferred stock. The company formed FOXO Acquisition Corporation and issued Series E preferred (2.5% cash dividend, 5% common stock dividend, secured; nonconvertible). FOXO lost its NYSE American listing in Q3 2025 and says an uplist is possible but not certain.

FOXO Technologies (OTC: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, was recognized by the Rural Health Association of Tennessee (RHA) at the RHA Annual Conference Awards Luncheon on Dec. 9, 2025.

Myrtle was noted for ongoing community engagement and sharing lessons learned after marking two years of accepting patients in August and serving individuals from 63 of Tennessee’s 95 counties. Leadership said Myrtle operated at capacity for most of 2025 and plans to increase capacity and expand with additional facilities in coming years. Myrtle’s CEO Robert Merritt also presented on substance use disorder treatment and rural behavioral health stigma.

FOXO Technologies (OTCID: FOXO) has completed the acquisition of Vector Biosource Inc., a provider of information, data, and biospecimen sourcing services for biotechnology and pharmaceutical research industries. Vector reported Q2 2025 net revenues of $225,000 ($0.9M annualized).

The acquisition terms include $500,000 in cash, 60,000 shares of Series E Preferred Stock ($1.5M stated value), warrants for $2M of common stock at a 10% premium, and potential additional 80,000 preferred shares ($2M value) based on performance milestones. FOXO will also fund up to $1.2M for Vector's growth initiatives.

FOXO Technologies (OTC: FOXO) has signed a stock purchase agreement to acquire Vector Biosource Inc., a provider of information, data, and biospecimen sourcing services for biotechnology and pharmaceutical research industries. The acquisition terms include $500,000 in cash, 60,000 shares of Series E Preferred Stock ($1.5M stated value), warrants for $2M of common stock, and potential additional preferred shares worth up to $2M based on performance milestones.

Vector reported Q2 2025 revenues of $225,000 ($0.9M annual run rate) and is expected to grow significantly post-acquisition. FOXO has committed to funding up to $1.2M for Vector's growth initiatives. The closing is subject to due diligence completion and other conditions.

FOXO Technologies Inc. (NYSE:FOXO) has announced its delisting from NYSE American due to its stock price falling below the $0.10 minimum requirement. Trading of FOXO's Class A common stock was suspended on NYSE on August 12, 2025.

The Company has successfully secured approval to trade on the Over-the-Counter (OTC) market starting August 13, 2025, maintaining its "FOXO" trading symbol. CEO Seamus Lagan emphasized that despite the delisting, the company's business strategy and economic outlook remain unchanged, with plans to pursue potential acquisitions for growth and consider future NYSE or NASDAQ listing when appropriate.

FOXO Technologies (NYSE American: FOXO) has signed a non-binding agreement to acquire an assisted living and memory care facility in South Florida for $22 million. The facility features 87 licensed units for assisted living and memory care services. The purchase structure includes $5 million in non-convertible preferred stock, with a portion being milestone-based.

The company is also finalizing a previously announced acquisition of Vector Biosource, Inc., and pursuing expansion in assisted living and behavioral health sectors through its Myrtle Recovery Centers subsidiary. If current non-binding agreements are completed, FOXO will add over 350 units to its healthcare services portfolio. The company expects to file its Q2 2025 10-Q by August 14, projecting improved revenues and profitability.

FOXO Technologies Inc. (NYSE American: FOXO) announced that its Big South Fork Medical Center in Oneida, Tennessee has established a Performance Network Agreement with Covenant Health to provide swing bed services. The agreement enables the critical access designated rural hospital to offer post-acute care services to patients from Covenant Health's network, which serves greater Knoxville and East Tennessee.

The partnership aims to help patients who no longer require acute care to recover closer to their homes and families. This strategic move aligns with FOXO's organic growth strategy to increase net revenues at the hospital by expanding its service offerings through the Covenant Health performance network.

FOXO Technologies (NYSE American: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, has successfully renewed its operating license for its Oneida, Tennessee facility for another year. The renewal was granted by Tennessee's Department of Mental Health and Substance Abuse Services following a successful annual inspection.

The facility, which provides alcohol and drug residential treatment services, is currently operating at full capacity with a waiting list for future admissions. Management is actively exploring strategic expansion options, including opening a second location and potential acquisitions in the behavioral health sector.

FOXO Technologies Inc. (NYSE American: FOXO) has announced its Board's approval to pursue the spin-off of its subsidiary, FOXO Labs, Inc., which specializes in epigenetics technology. The subsidiary owns Patent No. 11,817,214 for machine learning models that determine biochemical states using DNA epigenetic data.

FOXO Labs utilizes saliva-based epigenetic biomarkers to provide health, lifestyle, and longevity insights, eliminating the need for invasive blood and urine collection. The company is developing an AI-powered health coaching system that combines wearable data with epigenetic analysis to deliver personalized wellness guidance.

The spin-off aims to create a subscription-based revenue model for personal health and longevity, with FOXO Technologies maintaining partial ownership while allowing shareholders to benefit from direct ownership in FOXO Labs.